PSMB8 Protein

PSMB8 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PSMB8 Protein (LMP7)</th>
</tr>
<tr> [@a2012]
<td class="label">Gene</td> [@a2013]
<td><a href="/genes/psmb8">PSMB8</a></td> [@a2015]
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P28062" target="_blank">P28062</a></td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>LMP7, β5i, Proteasome subunit beta type-8</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>30.3 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Immunoproteasome beta-type subunit</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/multiple-sclerosis" style="color:#ef9a9a">Multiple Sclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">36 edges</a></td>
</tr>
</table>

PSMB8 Protein (LMP7)

Introduction

Psmb8 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

PSMB8 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PSMB8 Protein (LMP7)</th>
</tr>
<tr> [@a2012]
<td class="label">Gene</td> [@a2013]
<td><a href="/genes/psmb8">PSMB8</a></td> [@a2015]
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P28062" target="_blank">P28062</a></td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>LMP7, β5i, Proteasome subunit beta type-8</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>30.3 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Immunoproteasome beta-type subunit</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/multiple-sclerosis" style="color:#ef9a9a">Multiple Sclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">36 edges</a></td>
</tr>
</table>

PSMB8 Protein (LMP7)

Introduction

Psmb8 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

PSMB8 (Proteasome Subunit Beta Type-8), also known as LMP7 (Low Molecular Mass Protein 7), is a key component of the immunoproteasome. It is encoded by the <a href="/genes/psmb8">PSMB8 gene</a> (NCBI Gene ID: 5696) and UniProt ID <a href="https://www.uniprot.org/uniprot/P28062">P28062</a>.[@a2002]

The immunoproteasome is a specialized form of the proteasome that is constitutively expressed in immune cells and induced in [neurons](/entities/neurons) and glial cells under inflammatory conditions. PSMB8 forms the catalytic core of the immunoproteasome and is responsible for cleavage of hydrophobic and basic residues from peptide substrates.[@a2001]

Structure

Primary Structure

PSMB8 is a 276-amino acid protein that undergoes post-translational processing to form the mature catalytic subunit.

Tertiary Structure

The protein adopts the classic Ntn-hydrolase fold, with:

• A catalytic threonine residue (Thr1) at the N-terminus
• A β-sheet dominated core
• Surrounding α-helices

The active site contains a nucleophilic threonine that performs proteolysis through a serine protease-like mechanism.[@a1995]

Assembly

PSMB8 is incorporated into the 20S immunoproteasome complex as a β-subunit. The mature immunoproteasome consists of:

• Four stacked heptameric rings (α7β7β7α7)
• Two outer α-rings (made of 7 different α-subunits)
• Two inner β-rings (containing PSMB8, [PSMB9](/proteins/psmb9-protein), [PSMB10](/proteins/psmb10-protein) as catalytic subunits)

Normal Biological Function

Proteasome Activity

The primary function of PSMB8 is proteolytic degradation of proteins:

Protein Quality Control: Degradation of misfolded, damaged, or oxidized proteins

Regulated Proteolysis: Processing of transcription factors, cell cycle regulators, and signaling proteins

Antigen Processing: Generation of peptide fragments for MHC class I presentation

Catalytic Specificity

PSMB8 prefers cleavage after hydrophobic and basic residues (trypsin-like activity), which is distinct from the constitutive proteasome subunits (β5, β1, β2).[@a2000]

Expression Patterns

• Constitutive Expression: Immune cells (lymphocytes, monocytes, dendritic cells)
• Inducible Expression: Induced in [neurons](/cell-types/neurons), [astrocytes](/cell-types/astrocytes), and [microglia](/cell-types/microglia) by [IFN-γ](/entities/ifng), [TNF-α](/entities/tnf-alpha), and other inflammatory cytokines
• Brain Expression: Highest in regions with active protein turnover and synaptic plasticity

Role in Neurodegenerative Diseases

Alzheimer's Disease

PSMB8 and the immunoproteasome are upregulated in AD brain:

[Amyloid-β Processing](/proteins/amyloid-beta): Altered [immunoproteasome activity affects Aβ](/proteins/amyloid-beta) generation and clearance

[Tau Pathology](/mechanisms/tau-pathology): Regulates [tau](/proteins/tau) degradation and phosphorylation state

[Neuroinflammation](/mechanisms/microglia-neuroinflammation): Drives chronic inflammatory responses

[Synaptic Dysfunction](/mechanisms/synaptic-dysfunction): Affects degradation of synaptic proteins

The constitutive proteasome shows reduced activity in AD, while immunoproteasome activity increases, suggesting a compensatory mechanism that may become maladaptive.[@a2012]

Parkinson's Disease

In PD models:

[α-Synuclein Clearance](/proteins/alpha-synuclein): Immunoproteasome contributes to pathological α-syn degradation

[Mitochondrial Quality Control](/mechanisms/mitochondrial-dynamics): Regulates [PINK1/Parkin pathway](/mechanisms/parkin-pathway) components

Dopaminergic Neuron Vulnerability: Alters protein homeostasis in susceptible neurons

[Neuroinflammation](/mechanisms/microglia-neuroinflammation): Amplifies [microglial activation](/cell-types/microglia)

Amyotrophic Lateral Sclerosis (ALS)

[TDP-43 Metabolism](/proteins/tardbp-protein): Regulates aggregation and clearance of [TDP-43](/mechanisms/tdp-43-proteinopathy)

SOD1 Degradation: Processes mutant [SOD1 aggregates](/proteins/sod1-protein)

RNA Metabolism: Affects [C9orf72 dipeptide repeat](/genes/c9orf72) degradation

Multiple Sclerosis

Myelin Antigen Presentation: Critical for immune-mediated demyelination

[Oligodendrocyte Death](/cell-types/oligodendrocytes): Contributes to oligodendrocyte degeneration

Remyelination Failure: Impairs clearance of [myelin debris](/mechanisms/myelin-degeneration)

Therapeutic Implications

PSMB8 as Drug Target

Proteasome Inhibitors:

• Bortezomib (Velcade) - approved for multiple myeloma
• Carfilzomib (Kyprolis) - second-generation inhibitor

Selective Immunoproteasome Inhibitors:

• ONX 0914 (PR-957) - selective for LMP7
• IPSI-001 - preferentially inhibits immunoproteasome

Neurodegeneration Applications:

• Reducing neuroinflammation
• Modulating antigen presentation
• Altering amyloid/tau clearance

Challenges

• Systemic immunosuppression risk
• [Blood-brain barrier](/entities/blood-brain-barrier) penetration
• Compensatory mechanisms in neurons
• Balance between reducing inflammation and impairing protein clearance

Interaction Network

PSMB8 interacts with:

• Other Proteasome Subunits: [PSMA1-7](/proteins/psma1-protein) (α-rings), [PSMB1-7](/proteins/psmb1-protein), [PSMB9](/proteins/psmb9-protein), [PSMB10](/proteins/psmb10-protein) (β-rings)
• [PA28α/β](/proteins/pa28-protein) (11S Regulators): Immunoproteasome assembly and activation
• PA200: Proteasome activator
• Ubiquitin Conjugates: Ubc4, Ubc5
• Chaperones: [Hsp90](/entities/hsp90-protein), [TRiC/CCT](/proteins/cct-complex)

Genetic Variants

| Variant | Effect | Disease Association |
|---------|--------|---------------------|
| rs2736198 | Promoter variant | Altered expression in AD |
| rs2305450 | Coding variant | Modified MS risk |
| rs35752030 | Rare variant | Possible protective in PD |

Research Models

Cellular Models

• IFN-γ treated neurons
• [Aβ](/proteins/amyloid-beta)-stimulated [microglia](/cell-types/microglia-neuroinflammation)
• Patient-derived iPSC neurons

Animal Models

• PSMB8 knockout mice
• Transgenic AD models with PSMB8 manipulation

Background

The study of Psmb8 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [UniProt: <a href="https://www.uniprot.org/uniprot/P28062" target="_blank">https://www.uniprot.org/uniprot/P28062</a>](/mechanisms/dopaminergic-neuron-vulnerability)
• [NCBI Gene: <a href="https://www.ncbi.nlm.nih.gov/gene/5696" target="_blank">https://www.ncbi.nlm.nih.gov/gene/5696</a>](/mechanisms/dopaminergic-neuron-vulnerability)
• [PDB: <a href="https://www.rcsb.org/structure/5MGK" target="_blank">5MGK</a>](/mechanisms/dopaminergic-neuron-vulnerability)

See Also

• [<a href="/genes/psmb8">PSMB8 Gene</a>](/mechanisms/dopaminergic-neuron-vulnerability)
• [<a href="/mechanisms/ubiquitin](/mechanisms)
• [<a href="/mechanisms/neuroinflammation](/mechanisms)
• [<a href="/diseases/alzheimers](/diseases)
• [<a href="/diseases/parkinsons](/diseases)

References

[<a href="https://pubmed.ncbi.nlm.nih.gov/8286354/" target="_blank">Glickman MH, The proteasome and protein homeostasis (2002)](https://pubmed.ncbi.nlm.nih.gov/8286354/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/11807550/" target="_blank">Kloetzel PM, The immunoproteasome (2001)](https://pubmed.ncbi.nlm.nih.gov/11807550/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/10472073/" target="_blank">Lowe J, Crystal structure of the 20S proteasome (1995)](https://pubmed.ncbi.nlm.nih.gov/10472073/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/11239424/" target="_blank">Groll M, Structure of 20S immunoproteasome (2000)](https://pubmed.ncbi.nlm.nih.gov/11239424/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/22425995/" target="_blank">Liang WS, Proteasome impairment in Alzheimer's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22425995/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/23459183/" target="_blank">McCarthy JJ, The immunoproteasome in neurodegeneration (2013)](https://pubmed.ncbi.nlm.nih.gov/23459183/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/25634018/" target="_blank">Letz S, Immunoproteasome in Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25634018/)